We are live on ! Find out more

BCAX

Bicara Therapeutics

BCAX

Market cap $1.48B

22.39 USD

+0.39

1.77%

At close Updated Sep 17, 12:26 PM EDT

1 day

1.77%

5 days

-3.86%

1 month

-10.22%

3 months

-2.31%

6 months

15.89%

Year to date

36.69%

1 year

104.1%

5 years

-4.36%

10 years

-4.36%

About: Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.

Employees: 103

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 66.7%

Negative 0%

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on September 1, 2026 to two new employees as a material inducement to employment under Bicara's 2026 Inducement Plan.

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective August 12, 2026, it awarded an inducement grant to Jennifer Larson under Bicara's 2026 Inducement Plan as a material inducement to her commencement of employment as Bicara's Chief Financial Officer. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $24.63 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on August 12, 2026.

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds

Bicara Therapeutics (BCAX) is upgraded to 'Buy' on favorable early clinical signals for ficerafusp alfa in head and neck cancer. BCAX's phase 1 data show promising median overall survival, but toxicity and small cohort size warrant caution ahead of pivotal phase 3 readout. Strong cash position ($500M liquidity) supports operations into 2029, enabling pursuit of interim phase 3 results and potential commercialization.

Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript

Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript

Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript

Bicara Therapeutics Q2 Earnings Call Highlights

Bicara Therapeutics NASDAQ: BCAX used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of ficerafusp alfa, or FICERA, while reaffirming its cash runway into the first half of 2029.

Bicara Therapeutics Q2 Earnings Call Highlights

Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report second quarter 2026 financial results and business updates before the market opens on Tuesday, August 11, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To access the live webcast, please visit the “Events & Presentations” section within the Investors page on the Bicara website. A replay of the webcast will be available for 30 days following the event.

Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the appointments of Jeremy Bender, Ph.D., MBA and Christy Oliger to its Board of Directors. Dr. Bender, who most recently served as Chief Executive Officer at Day One Biopharmaceuticals through its acquisition by Servier in 2026, brings more than 20 years of corporate strategy and operating experience in biotechnology to Bicara. Ms. Oliger brings more than 30 years of commercial and operating experience in global biopharmaceutical organizations, having most recently served as Senior Vice President of the Oncology Business Unit at Genentech.

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on July 1, 2026 to four new employees under Bicara's 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate, non-qualified stock options to purchase 191,425 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $28.91 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on July 1, 2026.

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

The Motley Fool

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?

CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20.04 per share on May 18, 2026. This represented 3.98% of Mazumdar's direct holdings prior to the transaction, with post-transaction direct ownership at 362,152 shares.

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?

See News Rankings

Price charts implemented using Lightweight Charts™